The big comeback for growth and a major setback for travel

The big comeback for growth and a major setback for travel

Equities 5 minutes to read
Picture of Peter Garnry
Peter Garnry

Chief Investment Strategist

Summary:  Our NextGen Medicine and Bubble Stocks theme baskets are the big winners in June as inflation expectations have fallen as more market participants are buying into the Fed narrative of transitory inflation and a more hawkish FOMC. We also take a quick look at Appian which is the best-performing stock within the Bubble Stocks basket. Finally, we are covering the recent declines in travel stocks due to the new emerging Covid-19 Delta variant that could negatively impact this year's summer holiday in Europe.


June manifested itself as the big comeback month for growth stocks with theme baskets such as NextGen Medicine (up 17.6% in June) and Bubble Stocks (up 10.3% in June) powering ahead fueled by a more hawkish FOMC causing long-term US interest rates and inflation expectations to decline. The NextGen Medicine basket got an additional boost from the major gene editing breakthrough by Intellia Therapeutics which we covered in yesterday’s equity update.

01_PG_1

Bubble stocks started their rebound back in mid-May and have since risen 21% likely causing a sigh of relief for Ark Invest and in general growth investors. While growth has staged a comeback and we believe investors should have these growth pockets in their portfolios, we are also still leaning towards inflation will run higher than current market consensus causing interest rates to climb higher over the coming year reducing the tailwind for growth stocks. Below the performance chart on our Bubble Stocks basket we have inserted the companies in the basket and if we look across performance last month the best-performing stock has been Appian.

Appian sells a low-code automation platform and solutions that maximizes resource use for businesses but has been under pressure since the peak back in February. In June, the stock finally rallied without any particular news until 17 June when the stock was added to Hedgeye’s new best idea long based on the views that Appian is doing the right things on pricing, community development and partner integration.

NameDomicileMkt Cap (USD mn.)12M Fwd EPS12M Fwd EV/SalesDiff to PT (%)5yr return (%)
Kuaishou TechnologyChina213,499-0.8516.260.3NA
Sea LtdSingapore140,384-1.2617.312.3NA
Airbnb IncUnited States130,635-1.3128.18.7NA
NIO IncChina94,795-1.5918.011.8NA
Snowflake IncUnited States84,570-0.8771.520.1NA
DoorDash IncUnited States67,743-0.1917.6-6.5NA
Roku IncUnited States59,111-0.2623.13.7NA
Bilibili IncChina51,601-4.7618.218.8NA
Teladoc Health IncUnited States41,124-0.3020.337.9928.6
XPeng IncChina37,228-2.4115.03.2NA
Affirm Holdings IncUnited States34,499-0.8939.714.3NA
BeiGene LtdChina34,490-9.7835.812.41,071.9
Unity Software IncUnited States34,299-0.3532.714.6NA
Plug Power IncUnited States32,156-0.1868.134.91,702.4
Seagen IncUnited States31,016-0.1115.916.3280.4
Cloudflare IncUnited States28,050-0.0846.1-5.6NA
Splunk IncUnited States27,486-0.2110.813.3166.0
MongoDB IncUnited States25,201-0.9834.11.4NA
Exact Sciences CorpUnited States24,752-1.1413.322.1915.2
Gaotu Techedu IncChina24,455-3.3411.8NANA
Farfetch LtdUnited Kingdom23,465-0.6610.321.2NA
DraftKings IncUnited States23,186-1.1626.531.9NA
GDS Holdings LtdChina20,998-0.1518.634.2NA
10X Genomics IncUnited States20,458-0.3238.97.7NA
Argenx SENetherlands19,397-10.72105.25.32,055.5
Alnylam Pharmaceuticals IncUnited States19,214-4.7721.02.8172.2
Ping An Healthcare and Technology Co LtdChina18,942-0.9111.627.8NA
Innovent Biologics IncChina18,305-0.6124.016.6NA
Guardant Health IncUnited States16,826-1.5040.532.0NA
Zai Lab LtdChina15,781-2.5287.58.4NA
Kingsoft Cloud Holdings LtdChina15,710-2.569.656.9NA
Yatsen Holding LtdChina15,665-1.1710.740.2NA
Oak Street Health IncUnited States15,461-0.4611.123.3NA
C3.ai IncUnited States15,370-0.7969.657.7NA
Bill.com Holdings IncUnited States15,319-0.1957.4-2.5NA
Canopy Growth CorpCanada15,279-0.9024.213.9990.2
Appian CorpUnited States15,229-0.4043.3-22.4NA
Avalara IncUnited States14,770-0.1621.314.3NA
Elastic NVUnited States14,429-0.4420.616.0NA
Cree IncUnited States14,240-0.5921.317.5296.1
Aggregate / median1,565,14121.314.6857.9

Source: Bloomberg and Saxo Group

01_PG_2
Source: Bloomberg

Delta variant is a key risk for travel stocks

The emerging Covid-19 variant called ‘Delta’ is coming a key risk for European tourism which is not only a blow to Southern Europe that is in desperate need of a rebound in their tourist income, but also travel stocks that are down 6.2% in June. While investors have reacted to the uncertainty selling off travel stocks, the recent data from the UK and Israel suggest that while new cases are increasing due to the new Delta variant the number of hospitalizations and severe cases of Covid-19 are not dramatically increasing suggesting that vaccinations are working. The recent selloff in travel stocks is healthy as the rebound in travel stocks has been too much relative to what we can expect of profitability and growth from the industry in the coming years.

01_PG_3
Source: Bloomberg

Quarterly Outlook

01 /

  • Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    Quarterly Outlook

    Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    John J. Hardy

    Global Head of Macro Strategy

  • Equity Outlook: The ride just got rougher

    Quarterly Outlook

    Equity Outlook: The ride just got rougher

    Charu Chanana

    Chief Investment Strategist

  • China Outlook: The choice between retaliation or de-escalation

    Quarterly Outlook

    China Outlook: The choice between retaliation or de-escalation

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: A bumpy road ahead calls for diversification

    Quarterly Outlook

    Commodity Outlook: A bumpy road ahead calls for diversification

    Ole Hansen

    Head of Commodity Strategy

  • FX outlook: Tariffs drive USD strength, until...?

    Quarterly Outlook

    FX outlook: Tariffs drive USD strength, until...?

    John J. Hardy

    Global Head of Macro Strategy

  • Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Quarterly Outlook

    Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Althea Spinozzi

    Head of Fixed Income Strategy

  • Equity Outlook: Will lower rates lift all boats in equities?

    Quarterly Outlook

    Equity Outlook: Will lower rates lift all boats in equities?

    Peter Garnry

    Chief Investment Strategist

    After a period of historically high equity index concentration driven by the 'Magnificent Seven' sto...
  • Commodity Outlook: Gold and silver continue to shine bright

    Quarterly Outlook

    Commodity Outlook: Gold and silver continue to shine bright

    Ole Hansen

    Head of Commodity Strategy

  • Macro Outlook: The US rate cut cycle has begun

    Quarterly Outlook

    Macro Outlook: The US rate cut cycle has begun

    Peter Garnry

    Chief Investment Strategist

    The Fed started the US rate cut cycle in Q3 and in this macro outlook we will explore how the rate c...
  • FX Outlook: USD in limbo amid political and policy jitters

    Quarterly Outlook

    FX Outlook: USD in limbo amid political and policy jitters

    Charu Chanana

    Chief Investment Strategist

    As we enter the final quarter of 2024, currency markets are set for heightened turbulence due to US ...

Content disclaimer

None of the information provided on this website constitutes an offer, solicitation, or endorsement to buy or sell any financial instrument, nor is it financial, investment, or trading advice. Saxo Bank A/S and its entities within the Saxo Bank Group provide execution-only services, with all trades and investments based on self-directed decisions. Analysis, research, and educational content is for informational purposes only and should not be considered advice nor a recommendation.

Saxo’s content may reflect the personal views of the author, which are subject to change without notice. Mentions of specific financial products are for illustrative purposes only and may serve to clarify financial literacy topics. Content classified as investment research is marketing material and does not meet legal requirements for independent research.

Before making any investment decisions, you should assess your own financial situation, needs, and objectives, and consider seeking independent professional advice. Saxo does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

Please refer to our full disclaimer and notification on non-independent investment research for more details.
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/legal/disclaimer/saxo-disclaimer)

Saxo Bank A/S (Headquarters)
Philip Heymans Alle 15
2900
Hellerup
Denmark

Contact Saxo

Select region

International
International

All trading and investing comes with risk, including but not limited to the potential to lose your entire invested amount.

Information on our international website (as selected from the globe drop-down) can be accessed worldwide and relates to Saxo Bank A/S as the parent company of the Saxo Bank Group. Any mention of the Saxo Bank Group refers to the overall organisation, including subsidiaries and branches under Saxo Bank A/S. Client agreements are made with the relevant Saxo entity based on your country of residence and are governed by the applicable laws of that entity's jurisdiction.

Apple and the Apple logo are trademarks of Apple Inc., registered in the US and other countries. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.